# A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

> **NCT06857695** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 8 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AZD5004 film-coated tablet
- **DRUG:** [14C]AZD5004 Solution for Infusion
- **DRUG:** [14C]AZD5004 Oral Solution

## Key facts

- **NCT ID:** NCT06857695
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-06
- **Primary completion:** 2025-05-05
- **Final completion:** 2025-05-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857695, "A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06857695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*